ASCO Annual Meeting brought many different updates to light in the realm of hematological malignancies, including multiple ...

Sanofi SNY announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (“CHMP”) has ...

Early intervention in high-risk smoldering myeloma with lenalidomide delays progression by up to 7 years and achieves ...

Renal failure in multiple myeloma typically occurs when the kidneys fail to filter waste products from the blood, leading to ...

Paris: Sanofi has announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has ...

Karolinska University Hospital has, for the first time in Sweden, begun preparations to treat a patient with multiple myeloma ...

Final results from the Phase II CONCEPT trial reveal that isatuximab combined with carfilzomib, lenalidomide, and ...

Sarclisa recommended for EU approval by the CHMP to treat transplant-eligible newly diagnosed multiple myeloma Recommendation based on GMMG-HD7 phase 3 study demonstrating that Sarclisa with VRd ...

Around 1,500 people with multiple myeloma will benefit from belantamab mafodotin, used in combination with bortezomib and ...

Multiple myeloma accounts for 15 per cent of all blood cancers and in recent years, its prevalence has risen sharply and is ...